G1LP34 Stock Overview
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Galapagos NV Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €7.46 |
| 52 Week High | €11.45 |
| 52 Week Low | €7.29 |
| Beta | 0.021 |
| 1 Month Change | -8.35% |
| 3 Month Change | -22.37% |
| 1 Year Change | -22.53% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -44.25% |
Recent News & Updates
Recent updates
Shareholder Returns
| G1LP34 | BR Biotechs | BR Market | |
|---|---|---|---|
| 7D | 1.1% | 3.2% | 1.4% |
| 1Y | -22.5% | -1.4% | 13.2% |
Return vs Industry: G1LP34 underperformed the BR Biotechs industry which returned -2.6% over the past year.
Return vs Market: G1LP34 underperformed the BR Market which returned 15.2% over the past year.
Price Volatility
| G1LP34 volatility | |
|---|---|
| G1LP34 Average Weekly Movement | 3.8% |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in BR Market | 9.0% |
| 10% least volatile stocks in BR Market | 2.2% |
Stable Share Price: G1LP34's share price has been volatile over the past 3 months.
Volatility Over Time: G1LP34's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 1,123 | Paul Stoffels | www.glpg.com |
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l.
Galapagos NV Fundamentals Summary
| G1LP34 fundamental statistics | |
|---|---|
| Market cap | R$9.70b |
| Earnings (TTM) | R$167.82m |
| Revenue (TTM) | R$1.33b |
57.8x
P/E Ratio7.3x
P/S RatioIs G1LP34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| G1LP34 income statement (TTM) | |
|---|---|
| Revenue | €243.58m |
| Cost of Revenue | €243.84m |
| Gross Profit | -€260.00k |
| Other Expenses | -€30.97m |
| Earnings | €30.71m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 01, 2024
| Earnings per share (EPS) | 0.47 |
| Gross Margin | -0.11% |
| Net Profit Margin | 12.61% |
| Debt/Equity Ratio | 0% |
How did G1LP34 perform over the long term?
See historical performance and comparison